Mohan Chilukuri, MD
Family Medicine · Durham, NCNPI 1407951882
Payments from drug & device makers
Across 291 payments — averaging $46.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$8K
- Novo Nordisk$1K
- Lilly USA, LLC$822
- Boehringer Ingelheim$542
- Abbott$531
- AstraZeneca$486
- plus $2K from 33 others
What the payments were for
- Consulting fees$6,18046%
- Travel & lodging$1,38510%
- Food & beverage$5,87144%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 11 | $7,658 |
| Novo Nordisk | 57 | $1,139 |
| Lilly USA, LLC | 44 | $822 |
| Boehringer Ingelheim | 28 | $542 |
| Abbott | 4 | $531 |
| AstraZeneca | 35 | $486 |
| AbbVie(2 entities) | 23 | $408 |
| Pfizer | 20 | $339 |
| Amgen(2 entities) | 6 | $235 |
| Johnson & Johnson | 9 | $147 |
| Lundbeck LLC | 1 | $138 |
| GSK | 7 | $119 |
| E.r. Squibb & Sons, L.L.C. | 5 | $101 |
| Merck | 6 | $84 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $56 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| Bayer | 3 | $50 |
| Boston Scientific | 1 | $49 |
| Sanofi Pasteur Inc. | 2 | $46 |
| Organon | 2 | $44 |
| Organogenesis Inc. | 1 | $37 |
| Mayne Pharma Commercial LLC | 1 | $35 |
| Cranial Technologies, Inc | 2 | $30 |
| Dexcom, Inc. | 2 | $29 |
| Nestle Healthcare Nutrition Inc. | 2 | $25 |
| Grifols USA, LLC | 1 | $25 |
| Viiv Healthcare Company | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| Roche Diagnostics Corporation | 1 | $20 |
| Astellas Pharma US Inc | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Exact Sciences | 1 | $18 |
| Baxter Healthcare | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| Gilead | 1 | $14 |
| Upsher-smith Laboratories LLC | 1 | $13 |
| Promius Pharma LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$439
- Repatha$150
- REXULTI$138
- RYBELSUS$122
- Wegovy$115
How this compares
$13,442 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 44 | $58,694 |
| EliquisApixaban | 62 | $55,857 |
| JardianceEmpagliflozin | 25 | $42,004 |
| JanuviaSitagliptin Phosphate | 42 | $31,868 |
| FarxigaDapagliflozin Propanediol | 24 | $25,135 |
| XareltoRivaroxaban | 24 | $16,574 |
| MounjaroTirzepatide | 12 | $16,413 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 27 | $5,945 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $5,842 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 17 | $5,501 |
| Carvedilol ErCarvedilol Phosphate | 11 | $5,242 |
| Atorvastatin Calcium | 321 | $3,066 |
| Amlodipine Besylate | 306 | $2,005 |
| Adacel TdapDiph,pertuss(Acell),tet Vac/Pf | 27 | $1,889 |
| Telmisartan | 41 | $1,514 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $339 | $61,35879 claims |
| Novo NordiskOzempic | $1,139 | $58,69444 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $542 | $47,84737 claims |
| MerckJanuvia | $84 | $31,86842 claims |
| AstraZenecaFarxiga | $486 | $25,13524 claims |
| Johnson & JohnsonXarelto | $147 | $16,57424 claims |
| Lilly USA, LLCMounjaro | $822 | $16,41312 claims |
| GSKShingrix | $119 | $5,94527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Durham
- Carmelita SwinerDurham$249K
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.